| Entry |
|
|---|
| Name |
Imatinib mesylate (USAN);
Imatinib mesilate (JAN);
Gleevec (TN);
Glivec (TN)
|
|---|
| Product |
|
|---|
| Generic |
IMATINIB (Dr.Reddy's Laboratories), IMATINIB MESYLATE (Mylan Institutional), IMATINIB MESYLATE (Mylan Pharmaceuticals), IMATINIB MESYLATE (American Health Packaging), IMATINIB MESYLATE (Apotex Corp), IMATINIB MESYLATE (AvPAK), IMATINIB MESYLATE (GSMS), IMATINIB MESYLATE (NorthStar RxLLC), IMATINIB MESYLATE (Sun Pharmaceutical Industries), IMATINIB MESYLATE (Teva Pharmaceuticals USA), IMATINIB MESYLATE (West-Ward Pharmaceuticals Corp) |
|---|
| Formula |
C29H31N7O. CH4SO3
|
|---|
| Exact mass |
589.2471
|
|---|
| Mol weight |
589.7084
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
Enzyme substrate
DG01633 CYP3A substrate
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG00710): | D01441<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Tyrosine kinase inhibitor |
|---|
| Disease |
Chronic myeloid leukemia (Philadelphia chromosome positive) [DS: H00004] Acute lymphoblastic leukemia (Philadelphia chromosome positive) [DS: H00001] Hypereosinophilic syndrome (FIP1L1-PDGFRA positive) [DS: H01599] Chronic eosinophilic leukemia (FIP1L1-PDGFRA positive) [DS: H01590] Gastrointestinal stromal tumors (KIT positive) [DS: H01591] |
|---|
| Target |
|
|---|
| Network |
| N10001 | First-generation tyrosine kinase inhibitor to BCR-ABL fusion |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinases inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XE Protein kinase inhibitors
L01XE01 Imatinib
D01441 Imatinib mesylate (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Imatinib
D01441 Imatinib mesylate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D01441 Imatinib mesylate (USAN); Imatinib mesilate (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
FIP1L1-PDGFRA
D01441 Imatinib mesylate (USAN) <JP/US>
KIT (CD117)
D01441 Imatinib mesylate (USAN) <JP/US>
Non-receptor tyrosine kinases
ABL family
BCR-ABL [HSA_VAR:25v1]
D01441 Imatinib mesylate (USAN) <JP/US>
Antineoplastics [br08340.html]
D01441
New drug approvals in the USA [br08319.html]
New Molecular Entity and New Therapeutic Biological Product Approvals
D01441
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01441
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01441
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01441
Pharmacogenomic biomarkers [br08341.html]
Companion diagnostics
D01441
 |
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 42
1 C8x C 33.4600 -13.6500
2 C8y C 33.4600 -12.2500
3 C8x C 32.2700 -11.5500
4 C8x C 31.0100 -12.2500
5 C8y C 31.0100 -13.6500
6 C8x C 32.2700 -14.3500
7 C5a C 29.8200 -14.3500
8 N1b N 28.6300 -13.6500
9 C8y C 27.4400 -14.3500
10 C8x C 26.1800 -13.6500
11 C8y C 24.9900 -14.3500
12 C8y C 24.9900 -15.7500
13 C8x C 26.1800 -16.4500
14 C8x C 27.4400 -15.7500
15 N1b N 23.8000 -13.7200
16 C8y C 22.5400 -14.4200
17 N5x N 21.3500 -13.7200
18 C8y C 20.1600 -14.4200
19 C8x C 20.1600 -15.8200
20 C8x C 21.3500 -16.5200
21 N5x N 22.5400 -15.8200
22 C8y C 18.9000 -13.7200
23 C8x C 18.9000 -12.3200
24 N5x N 17.7100 -11.6200
25 C8x C 16.5200 -12.3200
26 C8x C 16.5200 -13.7200
27 C8x C 17.7100 -14.4200
28 C1b C 34.6500 -11.5500
29 N1y N 35.9100 -12.2500
30 C1x C 35.9100 -13.6500
31 C1x C 37.1000 -14.3500
32 N1y N 38.2900 -13.6500
33 C1x C 38.2900 -12.2500
34 C1x C 37.1000 -11.5500
35 C1a C 39.5500 -14.3500
36 O5a O 29.8200 -15.7500
37 C1a C 23.8000 -16.4500
38 S4a S 34.9300 -16.5900
39 O1d O 34.9300 -15.1900
40 O1d O 34.9300 -17.9900
41 C1a C 33.5300 -16.5900
42 O1d O 36.3300 -16.5900
BOND 45
1 18 19 2
2 19 20 1
3 20 21 2
4 21 16 1
5 3 4 2
6 18 22 1
7 4 5 1
8 5 6 2
9 6 1 1
10 9 10 2
11 10 11 1
12 22 23 2
13 23 24 1
14 24 25 2
15 25 26 1
16 26 27 2
17 27 22 1
18 11 12 2
19 2 28 1
20 12 13 1
21 28 29 1
22 13 14 2
23 14 9 1
24 11 15 1
25 5 7 1
26 29 30 1
27 30 31 1
28 31 32 1
29 32 33 1
30 33 34 1
31 34 29 1
32 15 16 1
33 32 35 1
34 7 36 2
35 7 8 1
36 12 37 1
37 1 2 2
38 8 9 1
39 2 3 1
40 16 17 2
41 17 18 1
42 38 39 2
43 38 40 2
44 38 41 1
45 38 42 1
|
|---|
